Advertisement

Topics

BioTime Presents Updated OpRegen® Phase I/IIa Trial Data at AAO

08:00 EST 15 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
There were no treatment-related serious adverse events after 15 months Signs of engraftment and cell survival have been maintained BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnolo...

Other Sources for this Article

Investor Contact:
BioTime
David Nakasone, 510-871-4188
Dnakasone@biotime.com
Media Contact:
JQA Partners, Inc.
Jules Abraham, 917-885-7378
jabraham@jqapartners.com

NEXT ARTICLE

More From BioPortfolio on "BioTime Presents Updated OpRegen® Phase I/IIa Trial Data at AAO"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Ophthalmology
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...